Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: A pilot study

Oral Diseases

Volumn 20, Issue 5, 2014, Pages 477-481

  Czerninski, R ^a   Basile, J R ^b   Kartin Gabay, T ^a   Laviv, A ^c   Barak, V ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cytokines; Oncology; Oral lichen planus; Pathology; Squamous cell carcinoma antigen; Tumor markers

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; VASCULOTROPIN; INTERLEUKIN DERIVATIVE; TUMOR ANTIGEN; VASCULOTROPIN A;

ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LICHEN PLANUS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; BLOOD; FEMALE; MALE; MIDDLE AGED; MOUTH TUMOR; PILOT STUDY; SQUAMOUS CELL CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902076780     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12160     Document Type: Article

References (33)

1. Baay M, Brouwer A, Pauwels P et al (2011). Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol 2011: 565187.
2. Barak V, Goike H, Panaretakis KW et al (2004). Clinical utility of cytokeratins as tumor markers. Clin Biochem 37: 529-540.
3. Barak V, Selmi C, Schlesinger M et al (2009). Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 33: 178-182.
4. Barnes L, Eveson JW, Reichart PA et al, eds. (2005). World Health Organization classification of tumours: pathology and genetics of tumours of the head and neck. IARC: Lyon.
5. Brouns ER, Baart JA, Bloemena E et al (2012). The relevance of uniform reporting in oral leukoplakia: definition, certainty factor and staging based on experience with 275 patients. Med Oral Patol Oral Cir Bucal 18: e19-e26.
6. Carmeliet P, Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
7. Chen Z, Malhotra PS, Thomas GR et al (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379.
8. Deng Z, Hasegawa M, Yamashita Y et al (2012). Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci 103: 2127-2134.
9. Duffy SA, Taylor JM, Terrell JE et al (2008). Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113: 750-757.
10. Duk JM, De Bruijn HW, Groenier KH et al (1990). Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer 65: 1830-1837.
11. Duk JM, Groenier KH, de Bruijn HW et al (1996). Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14: 111-118.
12. Garcia-Garcia V, Bascones Martinez A, Martinelli-Klay CP et al (2012). New perspectives on the dynamic behaviour of oral lichen planus. Eur J Dermatol 22: 172-177.
13. Georgakopoulou EA, Achtari MD, Achtaris M et al (2012). Oral lichen planus as a preneoplastic inflammatory model. J Biomed Biotechnol 2012: 759626.
14. Gokhale AS, Haddad RI, Cavacini LA et al (2005). Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol 41: 70-76.
15. Kanazawa T, Nishino H, Hasegawa M et al (2007). Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264: 815-821.
16. Kato H, Torigoe T (1977). Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40: 1621-1628.
17. Kishimoto T (1989). The biology of interleukin-6. Blood 74: 1-10.
18. Lippman SM, Hong WK (2001). Molecular markers of the risk of oral cancer. N Engl J Med 344: 1323-1326.
19. Malhotra R, Patel V, Chikkaveeraiah VH et al (2012). Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array. Analytical Chem 84: 6249-6255.
20. Mao L, Hong WK, Papadimitrakopoulou VA (2004). Focus on head and neck cancer. Cancer Cell 5: 311-316.
21. van der Meij EH, Schepman KP, van der Waal I (2003). The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96: 164-171.
22. Meirovitz A, Kuten M, Billan S et al (2010). Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer-a prospective pilot study. Radiat Oncol 5: 16.
23. Molina R, Barak V, van Dalen A et al (2005). Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 26: 281-293.
24. Molina R, Jo J, Filella X et al (1999). C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 19: 2551-2555.
25. Otrock ZK, Hatoum HA, Musallam KM et al (2011). Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol 79: 103-111.
26. Pohl M, Werner N, Munding J et al (2011). Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol 49: 1398-1406.
27. Sawant SS, Zingde SM, Vaidya MM (2008). Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol 44: 722-732.
28. Sawhney H, Kumar CA (2011). Correlation of serum biomarkers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer. Cancer Biomark 10: 43-49.
29. Scambia G, Benedetti Panici P, Foti E et al (1994). Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 12: 2309-2316.
30. Shapira J, Berenstein-Ajzman G, Engelhard D et al (2003). Cytokine levels in gingival crevicular fluid of erupting primary teeth correlated with systemic disturbances accompanying teething. Pediatr Dent 25: 441-448.
31. van der Waal I (2010). Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol 46: 423-425.
32. Warnakulasuriya S, Johnson NW, van der Waal I (2007). Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36: 575-580.
33. Zhang HQ, Wang RB, Yan HJ et al (2012). Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev 13: 199-203.